Unum Therapeutics Inc. is changing its name to Cogent Biosciences Inc.

The biotechnology company's ticker symbol on the Nasdaq stock exchange will also change from UMRX to COGT, effective Oct. 6.

The name change follows the company's merger with privately held Kiq Bio LLC in July.

Cogent will continue as a precision therapy developer and focus on the development of lead asset PLX9486 to treat gastrointestinal stromal tumors. PLX9486 will also be renamed CGT9486 following the corporate name change.

The medicine is in a phase 1/2 trial, and the company expects to present data from the study at the 2020 Connective Tissue Oncology Society annual meeting.